Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05037097 · ClinicalTrials.gov registry record · Phase 1
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
A Phase 1 study, sponsored by Arcturus Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT05037097 is a Phase 1 study that has completed, run by Arcturus Therapeutics. The registered enrollment target is 72 participants.
The verdict
NCT05037097, a Phase 1 study, has completed, sponsored by Arcturus Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.
Interventions
- BIOLOGICAL ARCT-165
- BIOLOGICAL ARCT-154
- BIOLOGICAL ARCT-021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-08-30 |
| Est. Completion | 2023-12-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05037097
The ClinicalTrials.gov registry entry for NCT05037097 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcturus Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ARCT-165 is the first listed.
NCT05037097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05037097 about?
NCT05037097 is a clinical study titled "A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults". This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.
What is the current status of trial NCT05037097?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-08-30. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT05037097?
The interventions under investigation include: ARCT-165 (BIOLOGICAL), ARCT-154 (BIOLOGICAL), ARCT-021 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05037097?
This trial is sponsored by Arcturus Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.